Drug Discovery

TamRx launches to develop pipeline of immuno-oncology products for treatment of cancers

BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey, announced the formation of a new biotech start-up, TamRx.

Frazier Healthcare Partners launches Recida Therapeutics to develop therapeutics for serious antibiotic-resistant infections

Frazier Healthcare Partners has launched Recida Therapeutics, a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections.

GSK, Merck enter into €3.7bn deal for novel cancer treatment

GlaxoSmithKline (GSK) and Merck will develop and commercialize novel immunotherapy to treat multiple cancers, under €3.7bn worth deal.

Amprologix wins DHSC backing for new antibiotic

Frontier IP, a specialist in commercialising university intellectual property, today announces portfolio company Amprologix (the "Company") has won a contract worth £1.2 million funded by the UK Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs.

IQVIA to deliver clinical solutions for small biotech and biopharma firms

IQVIA has announced the launch of IQVIA Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies.

Caelum signs deal with Alexion to advance CAEL-101 development

Fortress Biotech, a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products, announced that Caelum Biosciences has signed a strategic agreement with Alexion Pharmaceuticals to advance the development of CAEL-101 for light chain (AL) amyloidosis.

Janssen, MeiraGTx sign $440m deal to develop gene therapy programs for IRDs

Janssen Pharmaceuticals and MeiraGTx have signed an agreement worth $440m to develop gene therapy programs for inherited retinal diseases (IRDs).

Dewpoint Therapeutics launches with $60m Series A to advance proprietary platform for drugging condensates

Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A.

Lyndra Therapeutics raises $55m in Series B financing

Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, has raised $55 million in Series B financing, funds it will use for Phase II clinical trials, expansion of its Phase I pipeline and manufacturing scale-up.